Case study: breakthrough mpox infection in Aotearoa New Zealand and Australia after completed two-dose course of subcutaneous modified vaccinia Ankara (MVA-BN) vaccines
This report describes the first case (in December 2022) of mpox occurring in Aotearoa, New Zealand, and Australia in a person who had completed a two-dose course of subcutaneous vaccination using modified vaccinia Ankara. He likely acquired his infection in the USA, was diagnosed in Auckland, and was followed-up in Australia, as he was travelling. This case highlights the importance of maintaining clinical suspicion for mpox in fully vaccinated individuals who present with symptoms suggestive of mpox and who have epidemiological risk.
Source: Sexual Health - Category: Sexual Medicine Authors: Vincent J. Cornelisse John J. M. Kearley Jose Vargas Castillo Lindsay Macharg Virginia A. McLaughlin Susan J. Jack Caitlin Swift Source Type: research
More News: Australia Health | Epidemiology | New Zealand Health | Sexual Medicine | Study | Vaccines